reported that the PFS rate at 5 years was higher in the CR and complete metabolic response groups than that in the PR/stable disease and noncomplete metabolic response groups at 1-year post-treatment initiation in patients treated with an anti–PD-1-based therapy having no tumor progression at 1 year. The gene discussed is PDCD1; the disease is neoplasm.